SCHEMBL931749

SCHEMBL931749

COC(CNc1ccccc1)OC

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.56
HTT P42858 2/20 0.46
SMN1; SMN2 Q16637 2/20 0.46
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
ALDH1A1 P00352 3/20 0.43
GAA P10253 1/20 0.41
RECQL P46063 1/20 0.41
RAB9A P51151 2/20 0.40
LMNA P02545 1/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
DNM1 Q05193 1/20 0.39
NPC1 O15118 1/20 0.39
HPGD P15428 1/20 0.39
AGTR1 P30556 1/20 0.39
TDP1 Q9NUW8 1/20 0.38
FNTA P49354 1/20 0.38
FNTB P49356 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1728835 0.85 HPGD (0.47) MAPTHTTSMN1; SMN2MEN1KMT2A
SCHEMBL1728640 0.80 NPC1 (0.55) MAPTSMN1; SMN2MEN1KMT2AALDH1A1
SCHEMBL935506 0.79 MAPT (0.49) MAPTHTTSMN1; SMN2MEN1KMT2A
SCHEMBL241292 0.79 MAPT (0.41) MAPTHTTMEN1KMT2AALDH1A1
SCHEMBL1728733 0.79 CA1 (0.47) MAPTHTTSMN1; SMN2MEN1KMT2A
SCHEMBL4147798 0.79 MAPT (0.37) MAPTHTTSMN1; SMN2MEN1KMT2A
SCHEMBL11079274 0.79 MAPT (0.58) MAPTHTTSMN1; SMN2ALDH1A1GAA
SCHEMBL3842708 0.76 MAPT (0.57) MAPTHTTMEN1KMT2AALDH1A1
SCHEMBL11592483 0.75 MAPT (0.49) MAPTHTTSMN1; SMN2MEN1KMT2A
SCHEMBL8575116 0.75 LOXL2 (0.40) MAPTMEN1KMT2AALDH1A1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2245000-B1 PROCESS OF PREPARATION OF OPTICALLY ACTIVE ALPHA AMINOACETALS CLARIANT SPECIALTY FINE CHEM F (FR) 2013-01-02 EP claimed
EP-4662204-A2 TELOMERASE INHIBITOR COMPOUNDS Geron Corporation (US) 2025-12-17 EP disclosed
US-20240343713-A1 TELOMERASE INHIBITOR COMPOUNDS BIOPHARMA CREDIT PLC [COLLATERAL AGENT] (GB) 2024-10-17 US disclosed
WO-2024168165-A2 TELOMERASE INHIBITOR COMPOUNDS GERON CORPORATION (US) 2024-08-15 WO disclosed
US-11773092-B1 Pyrido[3,4-b]indol-1-one compounds as antibacterial agents King Faisal University (SA) 2023-10-03 US disclosed
EP-3221297-A1 PROCESS FOR THE SYNTHESIS OF BENZAZEPINE DERIVATIVES Richter Gedeon Nyrt. (HU) 2017-09-27 EP disclosed
WO-2016079684-A1 PROCESS FOR THE SYNTHESIS OF BENZAZEPINE DERIVATIVES RICHTER GEDEON NYRT. (HU) 2016-05-26 WO disclosed
WO-2011006808-A1 CROSS-LINKABLE ORGANOSILICON-BASED COMPOSITIONS WACKER CHEMIE AG (DE) 2011-01-20 WO disclosed
EP-1831233-A2 METHOD FOR THE CONTINUOUS PRODUCTION OF SILICON COMPOUNDS CARRYING AMINO GROUPS Wacker Chemie AG (DE) 2007-09-12 EP disclosed
WO-2006063667-A2 METHOD FOR THE CONTINUOUS PRODUCTION OF SILICON COMPOUNDS CARRYING AMINO GROUPS WACKER CHEMIE AG (DE) 2006-06-22 WO disclosed
EP-0094181-A1 Use of thiadiazolylimidazolidinones to control aquatic vegetation ELI LILLY AND COMPANY (US) 1983-11-16 EP disclosed
EP-0093589-A1 Thiadiazolylimidazolidinones, intermediates, formulations and herbicidal method ELI LILLY AND COMPANY (US) 1983-11-09 EP disclosed
US-4093742-A Anti-hypertensive polyhaloisopropyl-substituted arylureas SCHERING CORPORATION (US) 1978-06-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11773092-B1 Pyrido[3,4-b]indol-1-one compounds as antibacterial agents IDO1, IDO2, IMPA1 MAPT 1581/4885HTT 4741/4885SMN1; SMN2 1660/4885
US-20240343713-A1 TELOMERASE INHIBITOR COMPOUNDS TERT, POT1, TERF2 MAPT 1007/4885HTT 369/4885SMN1; SMN2 411/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.